Abstract
Low birth weight (LBW, <2.50 kg) and preterm birth (PTB, <37 completed weeks of gestation) are important contributors to neonatal death. Newborn foot length has been assessed to identify LBW and PTB babies in Asia and Africa. The objectives of this observational study were to determine the diagnostic accuracy of foot length to identify LBW and PTB and to compare foot length measurements of a researcher with those of trained volunteers in Papua New Guinea. Newborn babies were enrolled prospectively with written informed consent from their mothers, who were participating in a clinical trial in Madang Province. The reference standards were birth weight, measured by electronic scales and gestational age at birth, based on ultrasound scan and last menstrual period at the first antenatal visit. Newborn foot length was measured within 72 hours of birth with a firm plastic ruler. Optimal foot length cut-off values for LBW and PTB were derived from receiver operating characteristic curve analysis. Bland-Altman analysis was used to assess inter-observer agreement between researcher and volunteer. From 12 October 2019 to 6 January 2021, we enrolled 342 newborns (80% of those eligible); 21.1% (72/342) were LBW and 7.3% (25/342) were PTB. The area under the curve for LBW was 87.0% (95% confidence intervals 82.8-90.2) and for PTB 85.6% (81.5-89.2). The optimal foot length cut-off was <7.7 cm for both LBW (sensitivity 84.7%, 74.7-91.2, specificity 69.6%, 63.9-74.8) and PTB (sensitivity 88.0% (70.0-95.8), specificity 61.8% (56.4-67.0). In 123 babies with paired measurements, the mean difference between the researcher and volunteer measurements was 0.07 cm (95% limits of agreement −0.55 to +0.70) and 7.3% (9/123) of the pairs were outside the 95% limits of agreement. When birth at a health facility is not possible, foot length measurement can identify LBW and PTB in newborns but needs appropriate training for community volunteers and evaluation of its impact on healthcare outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project received funding from a Swiss National Foundation Research for Development award (IZ07Z0_160909/1 to NL, ML), the Joint Global Health Trials scheme (UK Department for International Development, Medical Research Council, Wellcome Trust MR/N006089/1 to NL) and National Health and Medical Research Council, Australia (Project Grant 1084429 to LV). The funders were not involved in the design of the study, the collection, analysis, and interpretation of data, nor in the preparation of this manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Neofoot study protocol was approved by the Papua New Guinea Institute of Medical Research Institutional Review Board (IRB 1811) and the Papua New Guinea Medical Research Advisory Committee (MRAC 18.18). The Neofoot study is a substudy of the Women and Newborns Trail of Antenatal Intervention and Management (WANTAIM) study (ISRCTN37134032), which received ethical approval from the Institutional Review Board of the PNG Institute of Medical Research (IRB number 1608); the Medical Research Advisory Committee of the PNG National Department of Health (MRAC number 16.24); the Human Research Ethics Committee of the University of New South Wales (HREC number 16708); and the Research Ethics Committee of the London School of Hygiene and Tropical Medicine (REC number 12009)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Responds to referees' comments, corrects number and proportions of mothers with mild and moderate or severe anaemia (Table 1), and confidence interval of negative predictive value for birth weight cut-off (Table 3)
Data Availability
We will make the data publicly available on acceptance for publication on the Neofoot project page of the Open Science Framework (osf.io).
